Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 199)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 7
Gesamt: 285.538
Gesamt: 285.538
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: SPPI
1,0300
USD
0,00 %
0,0000 USD
Letzter Kurs 01.08.23 Nasdaq
Neuigkeiten
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9300 | -17,52 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
sieht doch gut aus im Amiland!!
SPPI 8.85 +0.637.70%
ich denke mal das wir heute noch die 9 sehen. Gruss Underground"
SPPI 8.85 +0.637.70% ich denke mal das wir heute noch die 9 sehen. Gruss Underground"
im Amiland ist alles möglich??
Vielleicht kriegen wir die Zulassung heute noch.. Nachbörslich?
Antwort auf Beitrag Nr.: 37.913.126 von Underground am 03.09.09 18:06:51Ja saublöd mit dem Video. Wenn ich den Links kopiere ist es am Ende und der nächste Beitrag beginnt. Mist.
Aber das The Street nun auch von 1MRD Dollar Peak Sales bei Zevalin spricht finde ich gut.
Man könnte ja fast meinen das hamse... (ne sag ich nicht)
Aber das The Street nun auch von 1MRD Dollar Peak Sales bei Zevalin spricht finde ich gut.
Man könnte ja fast meinen das hamse... (ne sag ich nicht)
hier in fast Deutsch!!Spektrum-pharmazeutische Produkte, zum sich am Rodman & darzustellen; Renshaw globale Investitions-Konferenz Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), eine Handels-stadium Biotechnologiefirma mit einem Fokus in der Onkologie, heute verkündet, dass ein Überblick über die Geschäftsstrategie der Firma am 11. jährlichen Rodman & dargestellt wird; Renshaw globale Investitions-Konferenz am Donnerstag, dem 10. September 2009 11:15 morgens zur östlichen Zeit. Die Konferenz wird im New- Yorkpalast-Hotel in New York City gehalten. Das Phasenwebcast von Spectrum' s-Darstellung ist bei http://www.sppirx.com vorhanden. Über Spektrum-pharmazeutische Produkte Wir sind eine Handels-stadium Biotechnologiefirma mit einem Fokus hauptsächlich in der Onkologie. Unsere Strategie wird vom Erwerb und vom Entwickeln einer ausgedehnten und verschiedenen Rohrleitung Spätstadium der klinischen und Handelsprodukte enthalten; Festlegung einer Handelsorganisation für unsere anerkannten Drogen; Fortfahren, eine Mannschaft mit Leuten zu errichten, die Fähigkeiten, Neigung, Verpflichtung demonstriert haben und eine Erfolgsbilanz des Erfolgs in unseren Bereichen des Fokus zu haben; und, die Sachkenntnis der Partner um die Welt wirksam einsetzend, um uns in der Durchführung unserer Strategie zu unterstützen. Zu mehr Information besichtigen Sie bitte unsere Web site bei www.sppirx.com.
Trading Spotlight
Hey!! habs gefunden, is ja voll der Kracher. Anschnallen und festhalten. ich denke mal das heute noch kräftig im Amiland eingekauft wird!! Good Luck and stay Long. Gruss Underground"
Good Luck and stay Long. Gruss Underground"
Antwort auf Beitrag Nr.: 37.912.950 von VaJo am 03.09.09 17:45:23Hey VaJo!! wo finde ich das Video?? Gruss
Nun sagt auch The Street - Zevalin Umsätze können 1 Milliarde Dollar erreichen! Kaufen!!
http://www.thestreet.com/_yahoo/video/10594196/bio-tech-high…
Schaut euch das Video an
http://www.thestreet.com/_yahoo/video/10594196/bio-tech-high…
Schaut euch das Video an
Bulletin
Investor AlertSign in
Become a MarketWatch member today
Front PageNews ViewerCommentaryMarketsInvestingPersonal FinanceCommunitypress release
Sep 3, 2009, 7:00 a.m. EST
Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
IRVINE, Calif., Sep 03, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company's business strategy will be presented at the 11th Annual Rodman & Renshaw Global Investment Conference on Thursday, September 10, 2009 at 11:15am Eastern Time. The conference is being held at the New York Palace Hotel in New York City.
The live webcast of Spectrum's presentation will be available at http://www.sppirx.com.
About Spectrum Pharmaceuticals
We are a commercial-stage biotechnology company with a focus primarily in oncology. Our strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for our approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in our areas of focus; and, leveraging the expertise of partners around the world to assist us in the execution of our strategy. For more information, please visit our website at www.sppirx.com.
Forward-looking statement -- This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. (TM), TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
(C) 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
SOURCE: Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Paul Arndt
Senior Manager, Investor Relations
949-788-6700x216
Gruss Underground
Investor AlertSign in
Become a MarketWatch member today
Front PageNews ViewerCommentaryMarketsInvestingPersonal FinanceCommunitypress release
Sep 3, 2009, 7:00 a.m. EST
Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
IRVINE, Calif., Sep 03, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company's business strategy will be presented at the 11th Annual Rodman & Renshaw Global Investment Conference on Thursday, September 10, 2009 at 11:15am Eastern Time. The conference is being held at the New York Palace Hotel in New York City.
The live webcast of Spectrum's presentation will be available at http://www.sppirx.com.
About Spectrum Pharmaceuticals
We are a commercial-stage biotechnology company with a focus primarily in oncology. Our strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for our approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in our areas of focus; and, leveraging the expertise of partners around the world to assist us in the execution of our strategy. For more information, please visit our website at www.sppirx.com.
Forward-looking statement -- This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. (TM), TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
(C) 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
SOURCE: Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Paul Arndt
Senior Manager, Investor Relations
949-788-6700x216
Gruss Underground
Antwort auf Beitrag Nr.: 37.908.431 von VaJo am 03.09.09 10:20:37und UP !
Durchsuchen
